← All trials
NCT05812014
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 25, 2023
- Primary completion
- Mar 31, 2024
- Completion date
- Jun 30, 2024
- First posted
- Apr 13, 2023
- Last posted
- Apr 19, 2023
- Enrollment
- 9800
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- AIM Therapeutics Inc.Collaborator
- Government of ChinaCollaborator
- Government of ChinaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.